研究溶栓治疗时既可有效溶栓 ,又能避免出血并发症的有效用药剂量。方法　对急性脑梗死患者应用体外血栓模型试验 ,分别测定患者加入溶栓药物和未加药物对照状态下的模型及有关的指标 ,寻找加入溶栓药的体外血栓模型处于溶栓状态时的溶栓药物用量。结果　在脑梗死时自然状态下和生理盐水对照时体外血栓湿重较低 ,临床不宜进行溶栓治疗。当加入尿激酶进行溶栓试验时 ,体外血栓湿重在主干支梗死患者比穿通支梗死患者降低的更明显。结论　主干支梗死时对静脉溶栓更敏感 ,如果加入尿激酶初始量时 ,患者体外血栓处于溶栓状态 ,则不能给予溶栓或应立即终止溶栓治疗 Study of thrombolytic therapy can effectively thrombolysis, but also to avoid bleeding complications of effective dosage. Methods In vitro thrombosis model tests were performed in patients with acute cerebral infarction. The models and related indexes of patients undergoing thrombolysis and non-drug control were determined, and the thrombolytic activity of thrombolytic drugs Drug dosage. Results in cerebral infarction when the natural state and physiological saline control when the in vitro thrombus wet weight is low, the clinical should not be thrombolytic therapy. When adding urokinase for thrombolysis, in vitro thrombus wet weight in patients with primary branch infarction than penetrating branch infarction patients decreased more obvious. Conclusions The main branch of the infarction is more sensitive to intravenous thrombolysis. If the initial amount of urokinase is added, the in vitro thrombus in the patient is in a thrombolytic state, and thrombolysis should not be given or the thrombolytic therapy should be terminated immediately